Discontinued — last reported Q4 '23
An increase suggests significant capital expenditure or investment in domestic production facilities and intellectual property, while a decrease may indicate asset divestiture or depreciation outpacing new investment.
This metric represents the total value of long-term assets held by the company within the United States geographic segme...
Comparable to long-term asset balances reported by other large-cap pharmaceutical firms for their primary domestic markets, often reflecting the intensity of local manufacturing and R&D footprint.
lly_segment_us_noncurrent_assets